The University of Chicago
Peter H. O’Donnell, MD, is a translational researcher with advanced training in clinical pharmacology and practicing medical oncologist specializing in the treatment of genitourinary malignancies, specifically bladder cancer.
Dr. O’Donnell has served as institutional principal investigator for numerous therapeutic clinical trials in urothelial (bladder) cancer, and co-authored publications from these studies that led to four FDA drug approvals of new therapies for urothelial cancer since 2016 (atezolizumab, durvalumab, pembrolizumab, and enfortumab vedotin).
At the University of Chicago, Dr. O’Donnell is Deputy Director of the Center for Personalized Therapeutics, Chair of the Committee on Clinical Pharmacology and Pharmacogenomics, and a member of the Comprehensive Cancer Center. Nationally, Dr. O’Donnell is the Chair of the Pharmacogenomics and Population Pharmacology Committee of The Alliance for Clinical Trials in Oncology.
Dr. O'Donnell has been recognized for outstanding contributions to research and education by being awarded the American Society of Clinical Pharmacology and Therapeutics Presidential Training Award, American Association of Cancer Researchers Future Leaders in Translational Medicine Award, and the Academy of Distinguished Medical Educators at The University of Chicago.
AbbVie (Allergan) (Individual(s) Involved: Self): Other Financial or Material Support, stock; Acerta Pharma (Individual(s) Involved: Self): Grant/Research Support; Astellas (Individual(s) Involved: Self): Advisory Board, Consultant, Grant/Research Support; AstraZeneca/MedImmune (Individual(s) Involved: Self): Grant/Research Support; Atheneum (Individual(s) Involved: Self): Consultant; Axiom Healthcare Strategies (Individual(s) Involved: Self): Consultant; Boehriner Ingelheim (Individual(s) Involved: Self): Grant/Research Support; Bristol Meyers Squibb (Individual(s) Involved: Self): Grant/Research Support; CLD (Individual(s) Involved: Self): Consultant; curio science (Individual(s) Involved: Self): Advisory Board; Dedham Group (Individual(s) Involved: Self): Consultant; Dragonfly (Individual(s) Involved: Self): DSMB, Other Financial or Material Support; EMD Serono (Individual(s) Involved: Self): Advisory Board, Grant/Research Support; G1 Therapeutics (Individual(s) Involved: Self): DSMB, Other Financial or Material Support; Genentech/Roche (Individual(s) Involved: Self): Advisory Board, Grant/Research Support; Health Advances: Consultant/Advisory Board; IntrinsiQ Specialty Solutions (Individual(s) Involved: Self): Advisory Board; Janssen (Individual(s) Involved: Self): Advisory Board; Merck (Individual(s) Involved: Self): Advisory Board, Consultant, Grant/Research Support; Nektar Therapeutics (Individual(s) Involved: Self): DSMB, Other Financial or Material Support; Pfizer (Individual(s) Involved: Self): Advisory Board; SeaGen (Individual(s) Involved: Self): Advisory Board, Consultant, Grant/Research Support
Wednesday, March 9, 2022
12:50 PM – 3:20 PM
Wednesday, March 9, 2022
2:22 PM – 2:29 PM
Wednesday, March 9, 2022
2:29 PM – 2:35 PM
Wednesday, March 9, 2022
2:35 PM – 3:20 PM